{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:08:44Z","timestamp":1773025724951,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA254961"],"award-info":[{"award-number":["R01CA254961"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.clml.2024.01.002","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T16:56:10Z","timestamp":1704560170000},"page":"298-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1227-7359","authenticated-orcid":false,"given":"Ibrahim","family":"Alodhaibi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel P.","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.01.002_bib0001","article-title":"Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma","volume":"29","author":"Ravi","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"10.1016\/j.clml.2024.01.002_bib0002","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.clml.2024.01.002_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1000106","article-title":"Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy","volume":"12","author":"Nair","year":"2022","journal-title":"Front Oncol"},{"issue":"20","key":"10.1016\/j.clml.2024.01.002_bib0004","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2011-09-377846","article-title":"Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy","volume":"119","author":"McBrayer","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.01.002_bib0005","doi-asserted-by":"crossref","first-page":"e25237","DOI":"10.1371\/journal.pone.0025237","article-title":"HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4","volume":"6","author":"Hresko","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.clml.2024.01.002_bib0006","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/BJ20140620","article-title":"Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria","volume":"462","author":"Bridges","year":"2014","journal-title":"Biochem J"},{"issue":"8","key":"10.1016\/j.clml.2024.01.002_bib0007","article-title":"Targeting mitochondrial complex i overcomes chemoresistance in high OXPHOS pancreatic cancer","volume":"1","author":"Masoud","year":"2020","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.clml.2024.01.002_bib0008","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-14-1088","article-title":"Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin","volume":"21","author":"Dalva-Aydemir","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.clml.2024.01.002_bib0009","first-page":"615","article-title":"HIV protease inhibitors for the treatment of multiple myeloma","volume":"17","author":"Mendez-Lopez","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"issue":"19","key":"10.1016\/j.clml.2024.01.002_bib0010","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood-2018-05-851170","article-title":"Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma","volume":"132","author":"Driessen","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.01.002_bib0011","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1038\/bcj.2013.2","article-title":"Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance","volume":"3","author":"Kraus","year":"2013","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.clml.2024.01.002_bib0012","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.01.002_bib0013","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.01.002_bib0014","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.3390\/cancers15123199","article-title":"Repurposing of chronically used drugs in cancer therapy: a chance to grasp","volume":"15","author":"Hijazi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2024.01.002_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.975912","article-title":"Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: a systematic review, meta-analysis and meta-regression of randomized controlled trials","volume":"13","author":"Nabrdalik","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.clml.2024.01.002_bib0016","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2165\/00003495-200059030-00014","article-title":"Nelfinavir: an update on its use in HIV infection","volume":"59","author":"Bardsley-Elliot","year":"2000","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.clml.2024.01.002_bib0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","article-title":"Ethical challenges with multiple myeloma bcma chimeric antigen receptor T cell slot allocation: a multi-institution experience","volume":"29","author":"Kourelis","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.clml.2024.01.002_bib0018","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/j.clml.2020.05.017","article-title":"Toxicities associated with metformin\/ritonavir combination treatment in relapsed\/refractory multiple myeloma","volume":"20","author":"Nathwani","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T02:27:22Z","timestamp":1713925642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024000193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2152265024000193"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}